English Español

Immune-monitoring of haemophilia A patients undergoing ITI

Despite clinical experience with the different protocols of ITI, little is known about the immunological mechanisms that cause the downregulation of FVIII-specific immune responses and the induction of long-lasting immune tolerance against FVIII. S. Lacroix-Desmazes will monitor and analyze the modifications of the immune system and the inflammatory status of the patient during the course of ITI.


Some clinically relevant immune markers (IMs) might help to predict the positive or negative outcome of the ITI.
The FVIII-inhibitor plasma may be able to affect the differentiation and maturation state of dendritic cells from healthy blood donors.


Both, cells and plasma collected during the course of ITI therapy will be required to study the IMs in haemophilia A patients with inhibitors. Depending on the amount of blood collected, the IMs will be studied with the following priority:

Also, quantitative measurements of different interleukins involved in the immune response including INF-γ, TGF-β1 and TNF-α in plasma will be done.

Literature overview:

Sébastien Lacroix-Desmazes Sébastien Lacroix-Desmazes
Paris, France